Qiagen delays U.S. launch of next-gen screening platform
This article was originally published in The Gray Sheet
Executive Summary
Qiagen says it will delay the U.S. launch of its QIAensemble SP/2000 next-generation screening and genotyping platform by about six months beyond its originally planned debut in the third-quarter of 2012. During the firm's second quarter earnings call Aug. 10, CEO Peer Schatz explained that the delay will ensure that the company can add Chlamydia trachomatis and Neisseria gonorrhoeae infection tests and other amplification-based assays, such as a newHPV eHC test, to system's assay menu. The firm reported second quarter sales of $262.7 million, up 9% from last year, or 11% on a constant currency basis. The total includes organic growth of about 5%, plus the benefit of recent acquisitions including DxS last September ("1The Gray Sheet" Sept. 28, 2009) and SABiosciences in November (2"The Gray Sheet" Nov. 16, 2009). However, due to particularly strong H1N1 flu test sales in 2009, organic growth would have been 10% excluding H1N1-related revenue, according to the company
You may also be interested in...
Qiagen Buys DxS, Boasts "Deepest" Personalized Medicine Testing Pipeline
Qiagen is boasting the "deepest" pipeline of molecular diagnostics for personalized medicine after acquiring test maker DxS for $95 million, plus up to $35 million in milestone payments
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.